Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Given Consensus Rating of “Hold” by Analysts

Share on StockTwits

Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) have earned a consensus recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company.

Several analysts recently issued reports on the company. Maxim Group downgraded Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, November 25th. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. ValuEngine raised shares of Adamis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Finally, Raymond James cut shares of Adamis Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 26th.

NASDAQ:ADMP traded down $0.01 on Friday, reaching $0.57. 561,161 shares of the company’s stock traded hands, compared to its average volume of 2,730,332. The company has a quick ratio of 1.46, a current ratio of 1.69 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $0.77 and a 200-day simple moving average of $1.03. The firm has a market cap of $35.91 million, a PE ratio of -0.57 and a beta of 1.31. Adamis Pharmaceuticals has a 12 month low of $0.48 and a 12 month high of $3.29.

Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Adamis Pharmaceuticals had a negative return on equity of 90.00% and a negative net margin of 175.77%. The business had revenue of $5.90 million during the quarter, compared to the consensus estimate of $6.55 million. On average, equities analysts anticipate that Adamis Pharmaceuticals will post -0.47 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMP. Vanguard Group Inc. grew its position in shares of Adamis Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,791,266 shares of the specialty pharmaceutical company’s stock valued at $2,328,000 after purchasing an additional 77,498 shares in the last quarter. BlackRock Inc. raised its position in Adamis Pharmaceuticals by 1.5% in the 2nd quarter. BlackRock Inc. now owns 962,687 shares of the specialty pharmaceutical company’s stock worth $1,252,000 after purchasing an additional 14,312 shares during the period. Morgan Stanley lifted its stake in Adamis Pharmaceuticals by 189.7% in the second quarter. Morgan Stanley now owns 757,124 shares of the specialty pharmaceutical company’s stock worth $984,000 after purchasing an additional 495,793 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Adamis Pharmaceuticals in the second quarter worth about $181,000. Finally, Wedbush Securities Inc. boosted its position in shares of Adamis Pharmaceuticals by 94.2% during the third quarter. Wedbush Securities Inc. now owns 86,600 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 42,000 shares during the period. 14.66% of the stock is owned by institutional investors and hedge funds.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Featured Article: How do candlesticks reflect price movement?

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Viomi Technology  Rating Increased to Hold at ValuEngine
Viomi Technology Rating Increased to Hold at ValuEngine
Barclays Lowers Vodafone Group  Price Target to GBX 190
Barclays Lowers Vodafone Group Price Target to GBX 190
John Wood Group  Stock Rating Reaffirmed by Jefferies Financial Group
John Wood Group Stock Rating Reaffirmed by Jefferies Financial Group
CoStar Group  Stock Rating Reaffirmed by Wells Fargo & Co
CoStar Group Stock Rating Reaffirmed by Wells Fargo & Co
Transcanna  Stock Price Down 13.9%
Transcanna Stock Price Down 13.9%
CT Real Estate Investment Trust  Hits New 52-Week High at $15.65
CT Real Estate Investment Trust Hits New 52-Week High at $15.65


© 2006-2019 Ticker Report